Recent clinical advances underscored that elimination of tumor-induced immunosuppression is prerequisite for successful therapy of advanced human cancers. The myeloid-derived suppressor cells (MDSCs) are one of the major populations limiting T cell-mediated antitumor immune responses in late-stage solid tumors, such as castration-resistant prostate cancers (CRPCs). Targeting MDSCs proved challenging due to their heterogeneity and phenotypic similarities with other myeloid cell lineages. Here, we identify a population of granulocytic MDSCs, which accumulate in patients' blood during progression of prostate cancer from localized to metastatic disease. The CRPC-associated MDSCs potently inhibit proliferation, IFN-γ and Granzyme-B production in autologous CD8 + T cells. Importantly, the MDSCs in blood and in lymph nodes of CRPC patients show high levels of activated STAT3 transcription factor, which is a crucial immune checkpoint regulator. We previously generated an original method to silence genes specifically in TLR9 + myeloid cells using CpG-siRNA conjugates [1, 2] . Now, we demonstrate that the CpG-STAT3siRNA is also effectively internalized by human MDSCs and induces STAT3 silencing without the need for transfection reagents. Our further studies demonstrated that twopronged TLR9-activation/STAT3-blocking by CpG-STAT3siRNA inhibits immunosuppressive effects of CRPC-MDSCs on CD8 + T cells, while both TLR9 triggering or STAT3 inhibition alone have only minimal effects. The reversal of MDSC immunosuppression by CpG-STAT3 siRNA results from reduced expression and enzymatic activity of Arginase I, a downstream STAT3 target gene. Overall, our study demonstrates the feasibility of overcoming immunosuppression in CRPC patients using CpG-STAT3siRNA strategy to alleviate effects of MDSCs. We anticipate that our strategy to reverse MDSCmediated immunosuppression without depleting myeloid cell populations will generate safer and more effective immunotherapy for late-stage, metastatic prostate cancers and potentially other solid tumors. References 1. Kortylewski M, Swiderski P, Herrmann A, et al: In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009, 27:925-932. 2. Zhang Q, Hossain DM, Nechaev S, et al: TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.
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